Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

Explore how LB Pharmaceuticals is revolutionizing the pharma industry with its innovative therapies for neuropsychiatric ...

The human body relies on three kinds of opioid receptors to regulate pain, much like traffic control systems on a busy highway. Understanding these pathways is key to developing safer pain treatments.

All prior antipsychotics have, in large part, relied on blocking this chemical messenger's receptors. Unlike previous generations of antipsychotics, Cobenfy doesn't directly interact with dopamine ...

All prior antipsychotics have, in large part, relied on blocking this chemical messenger’s receptors. Although they’re relatively effective at dimming hallucinations, antipsychotics struggle ...

Moreover, OPC-14597 shares some characteristics of other atypical antipsychotics with respect ... the known molecular isoforms of the dopamine receptors in several transfection systems, as well ...